As large datasets emerge from analyses of cardiac samples from patients with DD and/or COVID-19, cell-type composition shifts and BRD4-regulated gene signatures seen in CS-treated hCOs can be cross-validated with patient samples to address further the translational value of the organoid model. The gene discussed is BRD4; the disease is COVID-19.